An AstraZeneca, Merck drug slows the return of genetic breast cancer. Will testing speed up?
Bio Pharma Dive
JUNE 3, 2021
Study results disclosed ahead of ASCO could make Lynparza a standard "adjuvant" treatment for people with an inherited form of breast cancer — as long as they know they have it